Archives
-
Phosphatase Inhibitor Cocktail: Safeguarding Phosphorylation
2026-06-13
The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) from APExBIO sets a benchmark for reliable protein phosphorylation preservation in demanding workflows like immunoblotting and kinase activity assays. Its dual-tube design ensures broad-spectrum phosphatase inhibition, delivering reproducibility, sensitivity, and confidence for advanced signaling and stem cell studies.
-
Asunaprevir (BMS-650032): Potent HCV NS3 Protease Inhibitor
2026-06-12
Asunaprevir (BMS-650032) is a highly potent, orally bioavailable inhibitor of the hepatitis C virus (HCV) NS3 protease. It demonstrates broad genotype coverage and robust HCV RNA replication inhibition in diverse cell systems. Its mechanism is well characterized, and reliable benchmarks support its use in translational virology research.
-
Phosphatase Inhibitor Cocktail 3: Enhancing Phosphoprotein A
2026-06-12
Phosphatase Inhibitor Cocktail 3 (100X in DMSO) elevates the reproducibility and sensitivity of phosphoprotein workflows by safeguarding critical phosphorylation states during sample handling. Its broad-spectrum inhibition, particularly for serine/threonine phosphatases like PP1 and PP2A, ensures data integrity across Western blotting, kinase assays, and advanced signaling studies.
-
IBDV VP3 Protein Drives IRF7 Proteasomal Degradation in Chic
2026-06-11
This study elucidates how the infectious bursal disease virus (IBDV) uses its VP3 protein to promote the proteasome-dependent degradation of interferon regulatory factor 7 (IRF7), undermining type I interferon responses and facilitating viral replication in chicken cells. The findings clarify a molecular mechanism of viral immune evasion and provide actionable insights for researchers targeting the ubiquitin-proteasome system in host-pathogen interactions.
-
Calpain Inhibitor I, ALLN: Technical Guide for Apoptosis & I
2026-06-11
Calpain Inhibitor I, ALLN (SKU A2602) provides potent, selective inhibition of calpain and cathepsin proteases for researchers studying apoptosis and ischemia-reperfusion injury. It is best suited for workflows requiring precise control of proteolytic activity in cell-based and in vivo models, but is not recommended where aqueous solubility or clinical application is necessary.
-
NP-40 Lysis Buffer: Non-Denaturing Extraction for Complex Sa
2026-06-10
NP-40 Lysis Buffer from APExBIO stands out for its ability to gently lyse diverse cell types—animal, plant, fungal, and bacterial—while preserving native protein complexes for sensitive downstream analyses. Recent neuroinflammation research underscores its utility in co-immunoprecipitation and phosphoprotein studies, offering robust reproducibility and reduced background.
-
Phytol: RXR Activation, Mechanism, and Benchmarks (C5616)
2026-06-10
Phytol (C5616) is a natural diterpene alcohol that acts as a potent activator of retinoid X receptors (RXRs), with documented effects on nuclear hormone receptor activation and GABAergic modulation. Its precise molecular activity, solvent compatibility, and workflow parameters make it a robust tool for receptor signaling studies, as supported by product and peer-reviewed data.
-
Phosphatase Inhibitor Cocktail 2: Precision for Phosphorylat
2026-06-09
Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) from APExBIO preserves protein phosphorylation during demanding workflows, enabling accurate signal transduction and proteomics studies. This article highlights advanced use-cases, experimental enhancements, and troubleshooting tactics to maximize reproducibility and specificity in biochemical assays.
-
Disulfiram: Dopamine β-Hydroxylase Inhibitor in Cancer Workf
2026-06-09
Disulfiram is redefining cancer research as a multifaceted dopamine β-hydroxylase inhibitor and proteasome inhibitor, enabling targeted apoptotic cell death induction. This article delivers a detailed, evidence-driven protocol guide for maximizing Disulfiram’s utility in synthetic lethality studies, especially for APC-deficient colorectal and breast cancer models.
-
Disulfiram as a Dopamine β-Hydroxylase Inhibitor in Cancer R
2026-06-08
Disulfiram, a classic dopamine β-hydroxylase inhibitor, is redefining its role in cancer biology with robust synthetic lethality and proteasome inhibition. This article bridges bench workflows with recent mechanistic breakthroughs, offering actionable protocols and troubleshooting advice for maximizing Disulfiram's research value.
-
Saquinavir in Translational Research: Permeability, Mechanis
2026-06-08
Explore how Saquinavir, a leading HIV protease inhibitor, advances experimental antiretroviral research through the lens of cutting-edge permeability modeling and biomimetic assay design. This article delivers unique, actionable insights for scientists seeking to optimize study protocols and translational impact.
-
MLN4924 HCl Salt: Decoding Neddylation in Viral Immunity Res
2026-06-07
Explore how MLN4924 HCl salt—a potent NEDD8-activating enzyme inhibitor—enables advanced dissection of the neddylation pathway and viral immune evasion. Discover new assay strategies and translational insights not covered in standard cancer biology workflows.
-
Carfilzomib (PR-171): Precision Proteasome Inhibition Workfl
2026-06-06
Carfilzomib (PR-171) delivers robust, selective, and irreversible proteasome inhibition for cancer research, empowering reproducible results in cell viability, apoptosis, and tumor growth assays. Discover advanced workflows, troubleshooting strategies, and actionable protocol enhancements based on the latest preclinical insights.
-
Nirmatrelvir (PF-07321332): Protocols for SARS-CoV-2 Researc
2026-06-05
Nirmatrelvir (PF-07321332) has redefined experimental workflows for studying SARS-CoV-2 replication inhibition. This article unpacks applied research protocols, troubleshooting strategies, and the translation of molecular docking insights into robust assay design for antiviral therapeutics research.
-
RNA Pol II Inhibition Triggers Apoptosis Independent of Tran
2026-06-05
Harper et al. (2025) reveal that cell death following RNA Pol II inhibition is not a passive consequence of lost transcription, but an active, regulated apoptotic response initiated by the loss of hypophosphorylated RNA Pol IIA. This paradigm shift informs how cell death mechanisms are considered in cancer research and highlights new signaling axes for therapeutic exploration.